Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations

Loading...
Thumbnail Image

Date

2021

Journal Title

Journal ISSN

Volume Title

Publisher

BMC

Abstract

The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens.We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistanceassociated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations was addressed within the context of a 3D model of the HIV-1 IN complex and interaction analysis was performed using PyMol to validate DTG binding to the Wild type and seven mutant structures.

Description

Keywords

Cameroon, Molecular modelling, Dolutegravir drug, World Health Organization (WHO), HIV-1

Citation

Mikasi, S. G. et al. (2021). Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations. BMC Infectious Diseases, 21(1),379. https://doi.org/10.1186/s12879-021-06059-x